304 related articles for article (PubMed ID: 36161043)
21. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
[TBL] [Abstract][Full Text] [Related]
22. Proton Pump Inhibitor Treatment Has Little Effects on Secretion of Saliva in Patients with Proton Pump Inhibitor-Responsive Mild Reflux Esophagitis and Non-Erosive Reflux Disease.
Hoshikawa Y; Momma E; Hoshino S; Kawami N; Kitasako Y; Ikeda M; Iwakiri K
Digestion; 2023; 104(3):187-192. PubMed ID: 36580899
[TBL] [Abstract][Full Text] [Related]
23. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo
Schey R; Alla SP; Midani D; Parkman HP
Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
[TBL] [Abstract][Full Text] [Related]
24. Proton pump inhibitors in the management of gastroesophageal reflux disease.
Hrelja N; Zerem E
Med Arh; 2011; 65(1):52-5. PubMed ID: 21534455
[TBL] [Abstract][Full Text] [Related]
25. [Laparoscopic antireflux surgery for reflux esophagitis].
Yano F; Omura N; Yanaga K
Nihon Rinsho; 2016 Aug; 74(8):1316-1321. PubMed ID: 30562435
[TBL] [Abstract][Full Text] [Related]
26. Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.
Ribolsi M; Cicala M; Zentilin P; Neri M; Mauro A; Efthymakis K; Petitti T; Savarino V; Penagini R
Aliment Pharmacol Ther; 2018 Nov; 48(10):1074-1081. PubMed ID: 30294924
[TBL] [Abstract][Full Text] [Related]
27. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
[TBL] [Abstract][Full Text] [Related]
28. Review of the clinical development of fexuprazan for gastroesophageal reflux-related disease.
Ramani A; Merchant A; Cash BD
Eur J Clin Pharmacol; 2023 Aug; 79(8):1023-1029. PubMed ID: 37344679
[TBL] [Abstract][Full Text] [Related]
29. Evaluation and Treatment of Patients with Persistent Reflux Symptoms Despite Proton Pump Inhibitor Treatment.
Spechler SJ
Gastroenterol Clin North Am; 2020 Sep; 49(3):437-450. PubMed ID: 32718563
[TBL] [Abstract][Full Text] [Related]
30. Tegoprazan to treat gastroesophageal reflux disease.
Mermelstein J; Mermelstein AC; Chait MM
Drugs Today (Barc); 2020 Nov; 56(11):715-721. PubMed ID: 33332479
[TBL] [Abstract][Full Text] [Related]
31. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021.
Iwakiri K; Fujiwara Y; Manabe N; Ihara E; Kuribayashi S; Akiyama J; Kondo T; Yamashita H; Ishimura N; Kitasako Y; Iijima K; Koike T; Omura N; Nomura T; Kawamura O; Ohara S; Ozawa S; Kinoshita Y; Mochida S; Enomoto N; Shimosegawa T; Koike K
J Gastroenterol; 2022 Apr; 57(4):267-285. PubMed ID: 35226174
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art.
Savarino V; Marabotto E; Zentilin P; Demarzo MG; de Bortoli N; Savarino E
Drug Des Devel Ther; 2021; 15():1609-1621. PubMed ID: 33907381
[TBL] [Abstract][Full Text] [Related]
33. Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis.
Iwakiri K
J Nippon Med Sch; 2017; 84(5):209-214. PubMed ID: 29142181
[TBL] [Abstract][Full Text] [Related]
34. Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe.
Gyawali CP
Curr Gastroenterol Rep; 2017 Sep; 19(9):46. PubMed ID: 28780717
[TBL] [Abstract][Full Text] [Related]
35. Trends in proton pump inhibitor use, reflux esophagitis, and various upper gastrointestinal symptoms from 2010 to 2019 in Japan.
Yamamichi N; Shimamoto T; Takahashi Y; Takahashi M; Takeuchi C; Wada R; Fujishiro M
PLoS One; 2022; 17(6):e0270252. PubMed ID: 35714110
[TBL] [Abstract][Full Text] [Related]
36. [The role of the traditional surgical procedures for gastroesophageal reflux disease cannot be ignored].
Zhou JH; Tan QY
Zhonghua Wai Ke Za Zhi; 2020 Sep; 58(9):672-676. PubMed ID: 32878412
[TBL] [Abstract][Full Text] [Related]
37. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.
Ichikawa H; Sugimoto M; Sugimoto K; Andoh A; Furuta T
J Gastroenterol Hepatol; 2016 Apr; 31(4):716-26. PubMed ID: 26580676
[TBL] [Abstract][Full Text] [Related]
38. Evolving drugs in gastroesophageal reflux disease: pharmacologic treatment beyond proton pump inhibitors.
Johnson DA; Levy BH
Expert Opin Pharmacother; 2010 Jun; 11(9):1541-8. PubMed ID: 20450445
[TBL] [Abstract][Full Text] [Related]
39. Eosinophilic esophagitis: interactions with gastroesophageal reflux disease.
Cheng E; Souza RF; Spechler SJ
Gastroenterol Clin North Am; 2014 Jun; 43(2):243-56. PubMed ID: 24813513
[TBL] [Abstract][Full Text] [Related]
40. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.
Furuta T; Shimatani T; Sugimoto M; Ishihara S; Fujiwara Y; Kusano M; Koike T; Hongo M; Chiba T; Kinoshita Y;
J Gastroenterol; 2011 Nov; 46(11):1273-83. PubMed ID: 21861141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
